Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review.

Mirghani H, Albishi L, Alblewi SM

Frontiers in endocrinology19 Feb 2026

PMID41798193PMCIDPMC12960479DOI10.3389/fendo.2026.1777907PepBankPUB-41798193

Summary

IntroductionObesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents. This population often exhibits suboptimal glycemic control and diabetes-related complications. Glucagon-like peptide-1 receptor agonists (GLP-1 agonists) have emerged as a promising therapeutic option for pediatric patients due to their beneficial effects on weight reduction and glycemic regulation. Literature on this important issue is scarce. We aimed to assess the effects of GLP-1 agonists on body weight, HbA1c, body mass index z (BMI z), and systolic blood pressure (SBP). Additionally, we discussed adverse events and hypoglycemia.MethodsWe searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c. We retrieved 1600 articles. Out of the 44 reviews found, only 11 meta-analyses were included in the final results.ResultsGLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure, MD = 0.11, 95% CI 0.05-0.25, MD = 0.65, 95% CI 0.53-0.80, MD = 0.85, 95% CI 0.81-0.90, and MD = 0.19, 95% CI 0.04-83, respectively. The total adverse events and hypoglycemia were not different, log ratios=1.29, 95% CI 0.80-2.09, and log ratios=1.26, 95% CI 0.59-2.70, respectively.DiscussionGLP-1 agonists are a promising and effective therapy for lowering weight, HbA1c, BMI z, and SBP in adolescents with obesity or youth with type 2 DM. Moreover, GLP-1 agonists were well tolerated, and the total adverse events and hypoglycemia were comparable to those of controls.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study18

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone18

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists reduced body weight more than control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs reduced body weight more than control.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Comparator
Control
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight mean difference
0.11
reported reduction magnitude; unit not stated; 95% CI 0.05-0.25
Source sentences
Summary
GLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure, MD = 0.11, 95% CI 0.05-0.25, MD = 0.65, 95% CI 0.53-0.80, MD = 0.85, 95% CI 0.81-0.90, and MD = 0.19, 95% CI 0.04-83, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4179819301
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists reduced HbA1c more than control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs reduced HbA1c more than control.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
Control
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c mean difference
0.65
reported reduction magnitude; unit not stated; 95% CI 0.53-0.80
Source sentences
Summary
GLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure, MD = 0.11, 95% CI 0.05-0.25, MD = 0.65, 95% CI 0.53-0.80, MD = 0.85, 95% CI 0.81-0.90, and MD = 0.19, 95% CI 0.04-83, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4179819302
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists reduced BMI z more than control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs reduced BMI z more than control.
Peptide
Liraglutide
Outcome
DecreaseBMI z score
Study
n: not reported in source
Comparator
Control
Outcome group
Body weight · Metabolic and weight
Measurements
BMI z mean difference
0.85
reported reduction magnitude; unit not stated; 95% CI 0.81-0.90
Source sentences
Summary
GLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure, MD = 0.11, 95% CI 0.05-0.25, MD = 0.65, 95% CI 0.53-0.80, MD = 0.85, 95% CI 0.81-0.90, and MD = 0.19, 95% CI 0.04-83, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4179819303
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists reduced blood pressure more than control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs reduced blood pressure more than control.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Control
Outcome group
Blood pressure · Cardiovascular
Measurements
Blood pressure mean difference
0.19
reported reduction magnitude; unit not stated; 95% CI 0.04-83
Source sentences
Summary
GLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure, MD = 0.11, 95% CI 0.05-0.25, MD = 0.65, 95% CI 0.53-0.80, MD = 0.85, 95% CI 0.81-0.90, and MD = 0.19, 95% CI 0.04-83, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4179819304
05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists had total adverse events that were not different from control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs had no reported difference from control for total adverse events.
Peptide
Liraglutide
Outcome
No significant changeTotal adverse events
Study
n: not reported in source
Comparator
Control
Outcome group
Adverse events · Whole body
Measurements
Log ratio as labeled by source
1.29
total adverse events; 95% CI 0.80-2.09
Source sentences
Summary
The total adverse events and hypoglycemia were not different, log ratios=1.29, 95% CI 0.80-2.09, and log ratios=1.26, 95% CI 0.59-2.70, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4179819305
06HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists had hypoglycemia that was not different from control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs had no reported difference from control for hypoglycemia.
Peptide
Liraglutide
Outcome
No significant changeHypoglycemia
Study
n: not reported in source
Comparator
Control
Outcome group
Adverse events · Metabolic and weight
Measurements
Log ratio as labeled by source
1.26
hypoglycemia; 95% CI 0.59-2.70
Source sentences
Summary
The total adverse events and hypoglycemia were not different, log ratios=1.29, 95% CI 0.80-2.09, and log ratios=1.26, 95% CI 0.59-2.70, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4179819306
07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists reduced body weight more than control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs reduced body weight more than control.
Peptide
Semaglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Comparator
Control
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight mean difference
0.11
reported reduction magnitude; unit not stated; 95% CI 0.05-0.25
Source sentences
Summary
GLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure, MD = 0.11, 95% CI 0.05-0.25, MD = 0.65, 95% CI 0.53-0.80, MD = 0.85, 95% CI 0.81-0.90, and MD = 0.19, 95% CI 0.04-83, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4179819307
08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists reduced HbA1c more than control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs reduced HbA1c more than control.
Peptide
Semaglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
Control
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c mean difference
0.65
reported reduction magnitude; unit not stated; 95% CI 0.53-0.80
Source sentences
Summary
GLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure, MD = 0.11, 95% CI 0.05-0.25, MD = 0.65, 95% CI 0.53-0.80, MD = 0.85, 95% CI 0.81-0.90, and MD = 0.19, 95% CI 0.04-83, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4179819308
09HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists reduced BMI z more than control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs reduced BMI z more than control.
Peptide
Semaglutide
Outcome
DecreaseBMI z score
Study
n: not reported in source
Comparator
Control
Outcome group
Body weight · Metabolic and weight
Measurements
BMI z mean difference
0.85
reported reduction magnitude; unit not stated; 95% CI 0.81-0.90
Source sentences
Summary
GLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure, MD = 0.11, 95% CI 0.05-0.25, MD = 0.65, 95% CI 0.53-0.80, MD = 0.85, 95% CI 0.81-0.90, and MD = 0.19, 95% CI 0.04-83, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4179819309
10HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists reduced blood pressure more than control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs reduced blood pressure more than control.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Control
Outcome group
Blood pressure · Cardiovascular
Measurements
Blood pressure mean difference
0.19
reported reduction magnitude; unit not stated; 95% CI 0.04-83
Source sentences
Summary
GLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure, MD = 0.11, 95% CI 0.05-0.25, MD = 0.65, 95% CI 0.53-0.80, MD = 0.85, 95% CI 0.81-0.90, and MD = 0.19, 95% CI 0.04-83, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4179819310
11HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists had total adverse events that were not different from control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs had no reported difference from control for total adverse events.
Peptide
Semaglutide
Outcome
No significant changeTotal adverse events
Study
n: not reported in source
Comparator
Control
Outcome group
Adverse events · Whole body
Measurements
Log ratio as labeled by source
1.29
total adverse events; 95% CI 0.80-2.09
Source sentences
Summary
The total adverse events and hypoglycemia were not different, log ratios=1.29, 95% CI 0.80-2.09, and log ratios=1.26, 95% CI 0.59-2.70, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4179819311
12HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists had hypoglycemia that was not different from control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs had no reported difference from control for hypoglycemia.
Peptide
Semaglutide
Outcome
No significant changeHypoglycemia
Study
n: not reported in source
Comparator
Control
Outcome group
Adverse events · Metabolic and weight
Measurements
Log ratio as labeled by source
1.26
hypoglycemia; 95% CI 0.59-2.70
Source sentences
Summary
The total adverse events and hypoglycemia were not different, log ratios=1.29, 95% CI 0.80-2.09, and log ratios=1.26, 95% CI 0.59-2.70, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4179819312
13HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists reduced body weight more than control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs reduced body weight more than control.
Peptide
Tirzepatide
Outcome
DecreaseBody weight
Study
n: not reported in source
Comparator
Control
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight mean difference
0.11
reported reduction magnitude; unit not stated; 95% CI 0.05-0.25
Source sentences
Summary
GLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure, MD = 0.11, 95% CI 0.05-0.25, MD = 0.65, 95% CI 0.53-0.80, MD = 0.85, 95% CI 0.81-0.90, and MD = 0.19, 95% CI 0.04-83, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4179819313
14HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists reduced HbA1c more than control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs reduced HbA1c more than control.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
Control
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c mean difference
0.65
reported reduction magnitude; unit not stated; 95% CI 0.53-0.80
Source sentences
Summary
GLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure, MD = 0.11, 95% CI 0.05-0.25, MD = 0.65, 95% CI 0.53-0.80, MD = 0.85, 95% CI 0.81-0.90, and MD = 0.19, 95% CI 0.04-83, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4179819314
15HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists reduced BMI z more than control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs reduced BMI z more than control.
Peptide
Tirzepatide
Outcome
DecreaseBMI z score
Study
n: not reported in source
Comparator
Control
Outcome group
Body weight · Metabolic and weight
Measurements
BMI z mean difference
0.85
reported reduction magnitude; unit not stated; 95% CI 0.81-0.90
Source sentences
Summary
GLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure, MD = 0.11, 95% CI 0.05-0.25, MD = 0.65, 95% CI 0.53-0.80, MD = 0.85, 95% CI 0.81-0.90, and MD = 0.19, 95% CI 0.04-83, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4179819315
16HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists reduced blood pressure more than control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs reduced blood pressure more than control.
Peptide
Tirzepatide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Control
Outcome group
Blood pressure · Cardiovascular
Measurements
Blood pressure mean difference
0.19
reported reduction magnitude; unit not stated; 95% CI 0.04-83
Source sentences
Summary
GLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure, MD = 0.11, 95% CI 0.05-0.25, MD = 0.65, 95% CI 0.53-0.80, MD = 0.85, 95% CI 0.81-0.90, and MD = 0.19, 95% CI 0.04-83, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4179819316
17HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists had total adverse events that were not different from control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs had no reported difference from control for total adverse events.
Peptide
Tirzepatide
Outcome
No significant changeTotal adverse events
Study
n: not reported in source
Comparator
Control
Outcome group
Adverse events · Whole body
Measurements
Log ratio as labeled by source
1.29
total adverse events; 95% CI 0.80-2.09
Source sentences
Summary
The total adverse events and hypoglycemia were not different, log ratios=1.29, 95% CI 0.80-2.09, and log ratios=1.26, 95% CI 0.59-2.70, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4179819317
18HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In children and adolescents with obesity or type 2 diabetes, pooled GLP-1 agonists had hypoglycemia that was not different from control.
In plain wordsIn young people with obesity or type 2 diabetes, pooled GLP-1 drugs had no reported difference from control for hypoglycemia.
Peptide
Tirzepatide
Outcome
No significant changeHypoglycemia
Study
n: not reported in source
Comparator
Control
Outcome group
Adverse events · Metabolic and weight
Measurements
Log ratio as labeled by source
1.26
hypoglycemia; 95% CI 0.59-2.70
Source sentences
Summary
The total adverse events and hypoglycemia were not different, log ratios=1.29, 95% CI 0.80-2.09, and log ratios=1.26, 95% CI 0.59-2.70, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents.
Summary · context
We searched PubMed/MEDLINE, Web of Science, and the Cochrane Library from October to November 2025 using the following terms: GLP-1 agonists, semaglutide, tirzepatide, liraglutide, exenatide, children, obesity, adolescents, blood pressure, BMI z, hypoglycemia, body weight, and HbA1c.
Summary · context
Out of the 44 reviews found, only 11 meta-analyses were included in the final results.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4179819318

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.